Form 4: Zoetis Director Defers Equity Compensation

Zoetis Inc. Director Frank A. D'Amelio converted 1,619.3325 Restricted Stock Units into Deferred Stock Units through a voluntary deferral plan.

Summary

• Frank A. D'Amelio, a Director of Zoetis Inc., converted 1,619.3325 Restricted Stock Units (RSUs) into Deferred Stock Units (DSUs) on February 19, 2026.
• This conversion was a result of a voluntary deferral under the Zoetis Inc. Amended and Restated Non-Employee Director Deferred Compensation Plan.
• The newly acquired DSUs are fully vested and will be paid in a single lump sum within 30 business days following a Termination Event or a Change in Control.
• Following this transaction, D'Amelio's total beneficially owned DSUs increased to 11,620.8453, which includes 10,001.5128 previously granted DSUs.
• He also holds 10,142.8688 DSUs from the 2013 Equity and Incentive Plan and 1,936 RSUs that are scheduled to vest on February 18, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine compensation transaction for a director, with no immediate positive or negative implications for the company's operational or financial performance.

Positives

• The director's decision to defer compensation into DSUs indicates a long-term commitment to Zoetis Inc. and aligns his interests with shareholders.
• The newly acquired DSUs are fully vested, providing certainty regarding the director's future equity stake.

Future Outlook

The filing details future vesting and settlement dates for equity compensation, specifically the vesting of 1,936 RSUs on February 18, 2026, and the settlement terms for the deferred stock units upon a termination event or change in control.

Industry Context

StockSavvy.ai notes that the deferral of equity compensation into deferred stock units is a common practice among corporate directors, particularly for non-employee directors. This mechanism allows directors to defer income and align their long-term interests with the company's performance, often until their separation from service. This practice is consistent with corporate governance trends aimed at fostering long-term commitment.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Deferred Stock Units (DSUs) for director compensation is a standard practice across many large-cap companies in the pharmaceutical and animal health sectors, similar to companies like Merck & Co. (MRK) or Elanco Animal Health (ELAN).
• Voluntary deferral plans, such as the one utilized by Zoetis, are common mechanisms for directors to manage their equity compensation and tax obligations, aligning with best practices seen in companies like Pfizer (PFE), from which Zoetis was spun off.

Stakeholder Impact

• Shareholders: The deferral of equity compensation aligns the director's long-term interests with shareholder value, as the DSUs are tied to the company's stock performance.
• Employees: No direct impact on employees is indicated by this director compensation filing.

Next Steps

• Settlement of 1,936 Restricted Stock Units (RSUs) on February 18, 2026, subject to continued service.
• Payment of Deferred Stock Units (DSUs) in a single lump sum within 30 business days following a Termination Event or a Change in Control.
• Settlement of other Deferred Stock Units (DSUs) upon the reporting person's separation from service as a director.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation deferral for a director and does not contain information that would significantly alter the investment thesis for Zoetis Inc. It reflects standard corporate governance practices and does not provide new insights into the company's operational performance or future prospects that would warrant a change in investment recommendation.

Keywords

Zoetis, ZTS, Form 4, Director Compensation, Restricted Stock Units, Deferred Stock Units, Equity Compensation, Stock Deferral